YMAB - Y-mAbs Therapeutics, Inc.
IEX Last Trade
13.595
0 0%
Share volume: 0
Last Updated: Fri 20 Dec 2024 09:18:12 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.46%
PREVIOUS CLOSE
CHG
CHG%
$13.60
-5.10
0.60%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-07 | 2023-03-30 | 2023-05-08 | 2023-08-10 | 2023-11-13 | 2024-02-29 | 2024-05-07 | |
| Assets | |||||||||
| Total Assets | 165.178 M | 143.915 M | 141.456 M | 137.445 M | 132.396 M | 128.884 M | 127.869 M | 123.315 M | |
| Current Assets | 153.920 M | 133.244 M | 130.447 M | 124.006 M | 115.784 M | 114.860 M | 111.111 M | 108.267 M | |
| Inventories | 6.794 M | 6.242 M | 6.702 M | 8.945 M | 5.187 M | 7.113 M | 5.065 M | 8.448 M | |
| Other Current Assets | 6.253 M | 3.225 M | 5.452 M | 3.730 M | 3.570 M | 2.302 M | 4.955 M | 3.482 M | |
| Short Term Investments | 6.253 M | 3.225 M | 5.452 M | 3.730 M | 3.570 M | 2.302 M | 4.955 M | 3.482 M | |
| Total Receivables | 7.208 M | 9.251 M | 12.531 M | 18.702 M | 19.118 M | 18.874 M | 22.454 M | 20.588 M | |
| Current Cash | 133.665 M | 114.526 M | 105.762 M | 92.629 M | 87.909 M | 86.571 M | 78.637 M | 75.749 M | |
| Total Non-current Assets | 11.258 M | 10.671 M | 11.009 M | 13.439 M | 16.612 M | 14.024 M | 16.758 M | 15.048 M | |
| Property Plant Equipment | 1.554 M | 1.372 M | 604.000 K | 511.000 K | 375.000 K | 296.000 K | 224.000 K | 153.000 K | |
| Other Assets | 8.130 M | 7.769 M | 7.419 M | 10.030 M | 13.428 M | 11.008 M | 13.903 M | 12.352 M | |
| Intangible Assets | 1.574 M | 1.530 M | 2.986 M | 2.898 M | 2.809 M | 2.720 M | 2.631 M | 2.543 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 165.178 M | 143.915 M | 141.456 M | 137.445 M | 132.396 M | 128.884 M | 127.869 M | 123.315 M | |
| Total liabilities | 33.782 M | 36.017 M | 32.235 M | 29.616 M | 27.715 M | 28.734 M | 26.884 M | 24.126 M | |
| Total current liabilities | 29.450 M | 32.015 M | 28.284 M | 25.920 M | 24.233 M | 21.812 M | 20.128 M | 17.605 M | |
| Accounts Payable | 11.291 M | 13.723 M | 14.175 M | 8.843 M | 7.252 M | 7.610 M | 6.060 M | 6.728 M | |
| Other liabilities | 3.030 M | 2.983 M | 3.052 M | 3.067 M | 3.066 M | 6.197 M | 6.239 M | 6.228 M | |
| Current long term debt | 1.092 M | 1.200 M | 868.000 K | 855.000 K | 829.000 K | 898.000 K | 902.000 K | 888.000 K | |
| Long term debt | 1.302 M | 1.019 M | 899.000 K | 629.000 K | 416.000 K | 725.000 K | 517.000 K | 293.000 K | |
| Other liabilities | 3.030 M | 2.983 M | 3.052 M | 3.067 M | 3.066 M | 6.197 M | 6.239 M | 6.228 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 131.396 M | 107.898 M | 109.221 M | 107.829 M | 104.681 M | 100.150 M | 100.985 M | 99.189 M | |
| Common stock | 43.719 M | 43.718 M | 43.668 M | 43.672 M | 43.663 M | 43.621 M | 43.626 M | 43.779 M | |
| Retained earnings | -409.674 M | -437.200 M | -436.043 M | -442.433 M | -448.735 M | -456.482 M | -457.470 M | -464.099 M |